# Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

> **NCT01794299** · PHASE2 · COMPLETED · sponsor: **Kiadis Pharma** · enrollment: 31 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** ATIR

## Key facts

- **NCT ID:** NCT01794299
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-06
- **Final completion:** 2017-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794299, "Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01794299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*